Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.
|Grade||Last Price||% Change||$ Change|
ACRX closed up 3.39 percent on Wednesday, March 22, 2017, on 74 percent of normal volume. It was able to find support at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Trend Table & Recent Alerts
|Weak or Absent||Down||Up||Down|
|See historical ACRX trend table...|
|Date||Alert Name||Type||% Chg|
|Mar 22||50 DMA Support||Bullish||0.00%|
|Mar 22||200 DMA Resistance||Bearish||0.00%|
|Mar 22||Stochastic Buy Signal||Bullish||0.00%|
|Mar 22||Lower Bollinger Band Walk||Other||0.00%|
|Mar 21||50 DMA Support||Bullish||3.39%|
|Mar 21||200 DMA Resistance||Bearish||3.39%|
|Mar 20||200 DMA Resistance||Bearish||0.00%|
|Mar 20||Shooting Star Candlestick||Bearish||0.00%|
|Mar 20||Bollinger Band Squeeze||Range Contraction||0.00%|
|Mar 17||NR7||Range Contraction||1.67%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The companys principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physicians office. In addition, the companys product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACRX news...
|52 Week High||4.08|
|52 Week Low||2.4|
|200-Day Moving Average||3.0988|
|50-Day Moving Average||2.957|
|20-Day Moving Average||3.1175|
|10-Day Moving Average||3.08|
|Average True Range||0.1616|
|Chandelier Exit (Long, 3 ATRs)||3.1152|
|Chandelier Exit (Short, 3 ATRs)||3.3348|
|Upper Bollinger Band||3.3303|
|Lower Bollinger Band||2.9047|
|Percent B (%b)||0.34|